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Controversies on the therapeutic efficacy of lymph node dissection (LND) at time of radical 
nephrectomy (RN) for renal cell carcinoma (RCC) patients have not yet been solved, due to a limited 
knowledge of nodal dissemination patterns, thus licensing the use of unstandardized LND templates 
among institutions and causing post-operative patient risk-category misclassification. The aims of the 
thesis were I) to evaluate if the side and the location of RCC affected the probability of lymph nodal 
invasion (LNI) and/or nodal progression (NP) at follow-up, II) to describe nodal disease dissemination 
in clear cell RCC (ccRCC) patients and to assess the effect of the anatomical sites and the number of 
affected nodal areas on cancer specific mortality (CSM), III) to test the clinical usefulness of performing 
LND to stratify the risk of patients with RCC and select candidates for adjuvant treatment.  
Methods 
Core-data were represented by a prospectively collected database of 3,645 consecutive 
patients enrolled at a single tertiary Institution and submitted to surgery for RCC with comprehensive 
clinical, surgical, pathologic and follow-up data of patients. Regional LND consisted of hilar nodes 
plus, on the right side, pre-retro-caval nodes or, on the left side, para-aortic nodes. Extended LND 
consisted of regional LND plus interaortocaval nodes.  
Results  
Overall, 15% of patients underwent LND and were pN1 at surgery and during follow-up, 2.2% of 
patients had NP. Higher rates of LNI and NP were observed for patients with primary tumor located in 
more than one anatomical area relative to patients with tumor in a single area (p<0.01). Neither the 
RCC side nor the location reached the independent predictor status (all p>0.1). In the second study, 
among patients with one involved nodal site, 54 and 26% of patients were positive only in side-specific 
and interaortocaval station, respectively. Interaortocaval nodal positivity (HR 2.3, CI 95%: 1.3–3.9, 
p<0.01) represented an independent predictor of CSM. In the third study, LNI resulted as the most 
informative predictor of early progression (OR: 6.39; CI 95%: 3.26-12.54; p<0.0001). The accuracy 
was higher (p=0.008) for the model to predict early recurrence when implemented with pN (AUC: 0.76; 
CI95%: 0.71-0.80), as compared to the base model (AUC: 0.72; CI95%: 0.68-0.76). Patients with high-
risk disease showed a large difference in the risk of progression according to pN-status (1-year risk: 
58% for pN1; 31% for pN0; p<0.001). 
Conclusions 
Patients with single-side and more than one anatomical kidney area affected by RCC have higher rate 
of LNI at surgery and/or NP at follow-up, but this was predicted neither by side nor by location of RCC. 
When ccRCC patients (about 90% of all RCC) harbour nodal disease, its spreading can occur at any 
nodal station without involving the others. The presence of interoartocaval positive nodes does affect 
oncologic outcomes and therefore an extended LND template is advisable, when indicated. Moreover, 
performing LND at the time of RN improves risk stratification, resulting into clinical advantage for 





The role of lymph node dissection (LND) in patients submitted to surgery for renal cell carcinoma 
(RCC) has been extensively investigated but, although accepted as a staging procedure, its therapeutic 
effect is still a matter of debate1,2 
Since autoptic evaluations as well as sentinel node studies of pN1 disease dissemination in RCC 
patient ascertained unpredictable and extreme interindividual variability3-5, the aim of the first study 
was to investigate6 the role of anatomical side and location of the primary RCC, namely upper vs. 
middle vs. lower vs. hilar vs. more than one kidney area, on the risk of lymph node invasion (LNI) 
and/or nodal progression (NP) during follow-up.  
Considering the weakness of Guidelines recommendations, as well as the conflicting results on 
survival from studies dealing with the topic of LND in kidney cancer, and taken into account the use of 
unstandardized LND templates among institutions and the inclusion of any kidney cancer histology, the 
aim of the second study7 was to describe nodal disease dissemination in clear cell RCC (ccRCC) patients 
and to assess the effect of the anatomical sites and the number of nodal areas affected on cancer specific 
mortality (CSM). 
Moreover, since LND could identify pN1 disease and thus high-risk patients, who may be 
candidates for adjuvant treatment, regardless of the other risk-factors (disease stage, Fuhrman grade 
and on the Eastern Cooperative Oncology Group Performance Status), the aim of the third study8 was 
to test the clinical usefulness of performing LND to stratify the risk of patients with RCC and select 




Material and methods 
Core-data were represented by a prospectively collected database of 3,645 consecutive 
patients enrolled at a single tertiary Institution and submitted to surgery for renal cell carcinoma with 
comprehensive clinical, surgical, pathologic and follow-up data of patients. 
In the first publication6, “The side and the location of the primary tumor does not affect the 
probability of lymph node invasion in patients with renal cell carcinoma”, namely 2485 patients with 
sporadic, unilateral RCC surgically treated at a single tertiary care referral center between 1987 and 
2016 were identified. Patients were staged preoperatively with CT or MRI of the abdomen. A clinically 
positive node was defined as the presence of at least one radiologically detected lymphadenopathy (>10 
mm) in the retroperitoneal lymphatic area at preoperative staging imaging. Regional LND consisted of 
hilar nodes plus, on the right side, pre-retro-caval nodes or, on the left side, para-aortic nodes. Extended 
LND consisted of regional LND plus interaortocaval nodes. The primary outcome of the study was 
represented by the presence of lymph node invasion (LNI) at final pathology and/or the presence of 
nodal progression (NP) during follow-up period after stratification for tumor side and location. 
In the second publication7, “The effect of anatomical location of lymph node metastases on 
cancer specific survival in patients with clear cell renal cell carcinoma”, data on 415 patients with 
sporadic, unilateral, ccRCC treated with open RN and eLND at two tertiary referral centers (1980-2012) 
were analysed. Outcomes of the study were represented by other cause mortality (OCM)- and cancer 
specific mortality (CSM)-free survival rate. Secondly, a description of the pattern of nodal cancer 
dissemination in pN1 patients was performed on the overall ccRCC population and after stratification 
according to the kidney tumour side (right vs. left). Finally, we assessed the CSM-free survival rate 
according to the pattern of nodal dissemination (lymph node site or number of lymph node areas 
involved).  
In the third publication8, “The critical role of lymph node dissection in selecting high-risk 
nonmetastatic renal cancer candidates for adjuvant therapy after nephrectomy”, 861 patients with 
nonmetastatic ccRCC treated with RN at a single academic center from 1987 to 2016 were identified. 
The follow-up was based on clinical evaluation and chest-abdomen CT scans performed at 3 to 6 months 
and at 12 months after surgery over the first year, and annually thereafter. Additional imaging 
assessments were performed if the patient’s symptoms raised clinical suspicion of relapse. Disease 
progression after surgery was defined as the evidence of retroperitoneal or distant recurrence 
demonstrable on imaging at least 1 month after treatment. A model including pT stage, disease grade 
and ECOG-PS was compared with the same model implemented with pN stage, in terms of the accuracy 
for predicting early disease progression after surgery, defined as relapse within 12 (±3) months post-
treatment. The accuracy of the predictive models was assessed by area under the curve (AUC). The 
accuracy of the models and decision curves was corrected for overfitting using 10-fold cross-validation.  
  
Results 
In the first study6, it was found that in patients with RCC, single-side tumors with involvement of 
more than one area, tend to have higher rates of nodal involvement relative to patients with single-area 
RCC location, either after stratification for the extent of LND (no LND vs. regional LND, namely, hilar 
LND plus, side specific pre/para-caval LND vs. extended LND, namely hilar LND plus side-specific, 
pre/paraaortic or pre/paracaval, and interaortocaval LND), or after exclusion of pT1a RCC. However, 
neither the side (left vs. right) nor the location (upper vs. middle vs. hilar vs. inferior area) of the primary 
RCC tumor represented independent predictors of the risk of harboring LNI at surgery and/or 
developing NP at follow-up. These figures suggested that anatomical location or side of the tumor are 
not reliable clinical parameters to identify patients who are at risk of nodal metastatic dissemination, 
but cM1 status, cN1 status, pT2 and pT3/pT4 disease, and Fuhrman grade 3/4.  
In the second study7, within the group of patients with one positive nodal area, in 54% of patients, 
nodal dissemination skipped the hilar nodal area, in line with what has been previously reported by 
EAU guidelines (35–45%)9, while in 26% of cases, both the hilar and the side-specific areas were 
eluded. Instead, when looking at patients with two nodal areas involved, hilar nodal area was skipped 
in 54% of patients and side-specific area only in 4% of cases. Moreover, after stratification for the 
ccRCC side, in case of interaortocaval-only nodal positivity among patients with one positive nodal 
site, 10 out of 12 patients had right ccRCC. This discrepancy was also identified in case of patients with 
two positive nodal areas and interaortocaval nodal involvement: the majority of patients had right 
ccRCC (14 out of 15 patients). On Multivariable Cox regression analyses, when considering the 
location of nodal metastases, independent predictors of CSM were represented by pT3 (HR: 2.7; CI 
95%: 1.5–5) and pT4 stage (HR: 6.1; CI 95%: 2.6–14.3), cM1 status (HR: 4.3; CI 95%: 3–6.2) and 
positive status of interaortocaval nodal area (HR: 2.3, CI 95%: 1.3–3.9), all p ≤ 0.01. These figures 
suggest that hilar LND could not be representative for every patient to be properly pN staged and 
thereafter to tailor adjuvant treatment. Among patients with right ccRCC and single nodal positive site, 
approximately 60% would have been properly staged as pN1 only by hilar and side-specific template, 
40% only by extended LND. Conversely, in left kidney tumors, 91% would have been properly staged 
as pN1 only by hilar and side-specific template, 9% only by extended LND, in line with previous 
results10. Moreover, cM1 disease, pT3-pT4 stage and positive interaortocaval nodal status and presence 
of any positive nodal area were independent predictors of CSM (all p ≤ 0.01), thus suggesting that 
extended LND could properly stage patients and tailor adjuvant treatment in the ccRCC population.  
In the third study8, the accuracy and clinical usefulness of a logistic regression model predicting 
disease progression within 12 months after surgery including factors defining high-risk patients 
according to the S-TRAC trial [(pT3 and Grade≥2 and performance status score ≥1) or pT4] relative to 
the base model plus pN stage for the prediction of early progression after surgery were compared. Nodal 
invasion resulted the most informative predictor of early progression (odds ratio: 6.39; 95% confidence 
interval [CI]: 3.26, 12.54; P < 0.0001). The accuracy was higher (P = 0.008) for the model implemented 
with pN (area under the curve: 0.76; 95% CI: 0.71, 0.80) as compared to the base model (area under 
the curve: 0.72; 95% CI: 0.68, 0.76). Performing LND to select patients for postoperative systemic 
treatment, resulted in a slightly higher net benefit as compared to a strategy defining risk on the base of 
factors other than pN. Patients with high-risk disease showed a large difference in the risk of progression 
according to pN-status (1-year risk: 58% [95% CI: 45, 72] for pN1; 31% [95% CI: 25, 38] for pN0; P 
< 0.001).   
Discussion 
The current Guidelines of the European Association of Urology9 suggest to offer an extended 
LND to patients with adverse clinical features, including a large diameter of the primary tumor (rating: 
weak), and in patients with cN1 disease only for staging purposes or local control (LE: 2b). Although 
the healthy nodal spreading pathways in kidney have been traced, autoptic evaluations as well as 
sentinel node studies of pN1 disease dissemination in patients with RCC ascertained unpredictable 
through extreme interindividual variability3-5. Indeed, renal lymphatic system follows the topography 
of renal vasculature11. From the right kidney, efferent lymphatic vessels running anterior to the renal 
vein (anterior bundles) can drain into paracaval, precaval, retrocaval and interaortocaval nodes. 
Retrocaval nodes are located close to the right crus of the diaphragm and connect with the thoracic duct. 
Lymphatics from the hilum running posterior to the renal vein but anterior to the pelvis of the kidney 
and the renal artery (intravascular bundles) are few in number. Their drainage is not well described. 
Lymphatic vessels travelling posterior to the renal artery (posterior bundles) drain to the paracaval, 
retrocaval and interaortocaval nodes. In some cases, posterior efferent lymphatic vessels have been 
observed curving superiorly through the right crus of the diaphragm and connecting directly to the 
thoracic duct without passing through any lymph nodes.  
From the left kidney, efferent lymphatic vessels running anterior to the renal vein can drain into the 
para-aortic and preaortic nodes. These vessels have also been observed to give off branches that run 
superiorly and connect with posterior draining efferent vessels. Intravascular bundles from the left 
kidney, like the right kidney, are few in number and not clearly described. Posterior efferent lymphatic 
vessels can drain to the para-aortic and retroaortic nodes. They can also curve superiorly through the 
left crus of the diaphragm and connect directly to the thoracic duct without passing through any lymph 
node. The retroperitoneal lymph nodes are an extensive network of lymphatics between the first and 
fifth lumbar vertebrae. They serve as the primary landing sites of renal lymph and have unpredictable 
interconnections before reaching the thoracic duct. In addition to draining the kidney, they also drain 
the sacrum, mesocolon, testicle, uterus, ovaries, adrenal glands, deep muscles of the dorsal region and 
the diaphragm12. Therefore the role of anatomical side and location of the primary RCC, namely upper 
vs. middle vs. lower vs. hilar vs. more than one kidney area, on the risk of lymph node invasion (LNI) 
and/or nodal progression (NP) during follow-up were investigated6. The first study did underline that 
lymph nodal invasion cannot be predicted by anatomical location or side of the tumor and identification 
of candidates for LND is mainly relying on disease features (cM1 status, cN1 status, pT2 and pT3/pT4 
disease, and Fuhrman grade 3/4), due to unpredictable and extreme interindividual variability. 
Evidence on the oncologic advantage of LND in RCC patients are mainly derived from the only 
randomized trial on the topic, European Organization for Research and Treatment of Cancer (EORTC) 
3088113, and prospective studies included in a recent metanalysis examining the role of LND in RCC1. 
It was found that LND and its extent are not associated with improved survival in either M0 or M1 RCC 
patients, but pN1 status is associated with adverse prognosis in M0 and M1 RCC, without increasing 
perioperative morbidity1. However, a re-analysis of the EORTC 30881 trial focusing on cT3 tumors, 
since roughly 70% of that study population would have been classified nowadays as cT1abN0M0, 
showed a 15% overall survival benefit at 5 years for LND recipients14. At the same time, the American 
Urological Association (AUA) and National Comprehensive Cancer Network (NCCN) Guidelines 
suggest to perform LND for staging and prognostic purposes, and recommend against routine LND in 
patients with clinically negative nodes15,16. The weakness of Guidelines recommendations, as well as 
conflicting results from studies dealing with the topic, is mainly linked to an unstandardized LND 
template/extent among institutions, stressing the anatomical unpredictability of nodal dissemination and 
the weighing of oncological benefits and the risk of surgical complications17. Moreover, each RCC 
histology subtype has different rates of LNI: the lowest rates are recorded for chromophobe (7%) and 
clear cell RCC (8.7%), while the highest for sarcomatoid (38.3%) and collecting duct RCC (71.4%)18. 
Therefore, in the second study7, nodal disease dissemination in clear cell RCC (ccRCC) patients 
submitted to LND was described and the effect of the anatomical sites and the number of nodal areas 
on cancer specific mortality (CSM) was evaluated. It was found that at least, 40% of patients with right 
and 9% with left ccRCC would not been staged as pN1 by a LND limited to hilar and side-specific 
lymph nodes, mainly due to a nodal-station-skipping phenomenon of metastasis. Moreover positive 
interaortocaval nodal status represented an independent predictor of CSM. Therefore, it seems advisable 
to perform an extended LND involving hilar, side-specific (pre/paraaortic or pre/paracaval) and 
interaortocaval LND, since this would aid patient risk stratification and multimodality upfront 
treatment. 
Since 30-35% of patients who undergo surgery for localized or locally advanced RCC will 
eventually develop recurrence (mostly in form of distant metastases), adjuvant treatment could reduce 
the risk of progression or cancer-related death. At the moment all tested adjuvant agents, except an 
autologous renal tumor cell vaccine and sunitinib, an inhibitor of the vascular endothelial growth factor 
receptor (VEGFR), sunitinib, have failed to show any benefit19. As far as sunitinib is concerned, the 
Food and Drug Administration approved the drug for this indication in 2017 due to a disease-free 
survival advantage over placebo as an adjuvant treatment after RN for high-risk renal cancer patients 
in the S-TRAC trial, whereas the European Medicines Agency did not20. The trial showed that patients 
treated with sunitinib had a 26% risk reduction of disease progression. Since the definition of high-risk 
disease was based on disease stage, Fuhrman grade and on the Eastern Cooperative Oncology Group 
(ECOG) Performance Status (PS) and patients with pN1 disease were classified as high-risk regardless 
of all other risk factors; as such, performing LND at the time of surgery could allow to detect patients 
with nodal metastases who may otherwise not be selected for adjuvant treatments21,22 on the solely base 
of T stage, disease grade and performance status. In this case nodal staging would greatly influence 
clinical practice; however, in the S-TRAC trial a LND was not routinely performed and not 
standardized, thus leaving the question unanswered. In the third study8, it was demonstrated that 
performing LND at the time of nephrectomy improves risk stratification, resulting into a small but 
nonnegligible clinical advantage for selecting high-risk patients for further treatment after surgery. If 
current adjuvant trials with immune checkpoint inhibition demonstrate a survival benefit over placebo, 
LND within these templates may regain an indication for proper risk and prognosis assessment and 
techniques to identify first landing sites of occult LN metastases may reduce the need for extensive 
templates. Indeed, implementation of the base model used to define high-risk patients in S-TRAC trial, 
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Abstract
Purpose To evaluate the role of side and location of the primary renal cell carcinoma (RCC) on the risk of lymph node 
invasion (LNI) and/or nodal progression (NP) during follow-up.
Materials and methods We evaluated 2485 patients with unilateral RCC, surgically treated in a single tertiary care refer-
ral center. Outcomes were LNI at surgery and/or NP during follow-up. We studied if RCC side (left vs. right) and location 
(upper vs. middle vs. hilar vs. lower area vs. more than one area) affected the probability of LNI and/or NP at follow-up.
Results Overall, 43 and 15% of patients underwent lymph node dissection and had LNI at surgery, respectively. During 
follow-up, 2.2% of patients had NP. Higher rates of LNI and NP were observed for patients with primary tumor located in 
more than one anatomical kidney area relative to patients with tumor in a single area (upper 11% vs. middle 10% vs. hilar 
0%, vs. lower 12% vs. more than one area 26%, p < 0.01). cM1, cN1, pT2/pT3/pT4 disease and Fuhrman grade 3/4 were 
independent predictors of the study outcome (all p ≤ 0.01). Neither the RCC side nor the location reached the independent 
predictor status (all p > 0.1).
Conclusions Patients with single-side and more than one anatomical kidney area affected by RCC have higher rate of LNI 
at surgery and/or NP at follow-up. Neither side nor location of primary RCC tumor is related to the risk of harboring LNI 
at surgery and/or developing NP at follow-up.
Keywords Lymph node invasion · Metastases · Kidney cancer · Renal cancer
Introduction
Over the last decades, a trend towards lower rate of lymph 
node dissection (LND) in renal cell carcinoma was observed 
due to lack of proven cancer control, widespread increase 
of minimally invasive surgery and stage migration [1, 2]. 
However, accurate nodal staging does maintain a key role 
for prognosis, follow-up schedule and, potentially, for con-
sideration of adjuvant therapy [3–5].
Cadaveric dissection and sentinel-node studies [6–9] 
demonstrated wide heterogeneity of retroperitoneal lym-
phatic drainage originating from kidney. In cadaveric dye 
studies, beyond the intrarenal crossing systems between hilar 
and intraparenchymatous drainage, it has been described that 
efferent kidney lymphatic system may reach either retrop-
eritoneal nodal landing sites or the thoracic duct, thus con-
necting directly with supraclavicular and mediastinal nodes 
[6]. Sentinel-node studies have indeed confirmed aberrant 
and unpredictable lymphatic spread with additional nodal 
invasion outside the respective locoregional retroperitoneal 
template in up to 35% cases (14/40) [9].
However, to the best of our knowledge, no study has ever 
addressed the issue whether the tumor side (right vs. left) 
and tumor location (upper vs. middle vs. hilar vs. lower area 
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vs. more than one kidney area) may be associated with the 
risk of lymph node invasion (LNI) at final pathology and/or 
nodal progression (NP) at follow-up.
Materials and methods
Patient population
After institutional review board approval, we identified 2485 
patients with sporadic, unilateral RCC surgically treated at a 
single tertiary care referral center between 1987 and 2016. 
Comprehensive clinical, surgical, pathologic and follow-up 
data of patients were collected and entered into a prospec-
tively maintained database. The decision to perform LND 
was customarily taken by the treating urologist and was 
based on the presence of cT2 disease and above, lymphad-
enopathies and/or palpable lymph nodes during surgery.
Clinical and pathologic evaluation
Dedicated genitourinary pathologists examined all surgical 
specimens. TNM stages and Fuhrman grades were assigned 
according to 8th American Joint Committee on Cancer 
classification [10] and to the World Health Organization/
International Society of Urological Pathology classification) 
[11]. Patients treated before the introduction of the most 
updated classification were reclassified. Clinical tumor size 
definition was based on pre-surgery imaging and was defined 
as the greatest tumor diameter in cm. Patients were staged 
preoperatively with CT or MRI of the abdomen. A clini-
cally positive node was defined as the presence of at least 
one radiologically detected lymphadenopathy (> 10 mm) in 
the retroperitoneal lymphatic area at preoperative staging 
imaging.
Template for lymph node dissection
The LND procedure consisted of excising the fibrofatty tis-
sue along anatomically defined areas (interaortocaval, pre-/
para-aortic, pre-/paracaval). Specifically, the interaortocaval 
region extended from the midline of the inferior vena cava 
to the midline of the aorta, the para-aortic region extended 
from the midline of the aorta to the left ureter, and the right 
precaval and paracaval nodal regions extended from the 
midline of the inferior vena cava to the right ureter. When 
an extended LND was sought, lymph nodes were collected 
according to the above-cited anatomical classification from 
the crus of the diaphragm to the aortic (left) or caval (right) 
bifurcation. Fat tissue containing lymph nodes from differ-
ent anatomical regions were sent in separate containers and 
fixed in 10% buffered formalin.
Outcomes and covariates
The primary outcome of the study was the presence of 
lymph node invasion (LNI) at final pathology and/or the 
presence of nodal progression (NP) during follow-up period. 
Covariates consisted of age, gender, tumor side (right vs. 
left), tumor location (upper vs. middle vs. hilar vs. lower 
area vs. more than one kidney area), the presence of symp-
toms at diagnosis, clinical metastatic status (cM0 vs. cM1), 
clinical nodal status (cN0 vs. cN1), pathological T stage 
(pT1 vs. pT2 vs. pT3/pT4), pathological N stage (pNx/pN0 
vs. pN1), Fuhrman grade (G3–G4 vs. G1–G2) [11], patho-
logical tumor size, number of removed and positive lymph 
nodes. Subgroup analyses on the overall population and after 
exclusion of pT1a RCC according to LND extent (no vs. 
regional vs. extended LND) were then performed to evaluate 
LNI and/or NP or only NP after stratification for the location 
of the tumor (superior vs. middle vs. hilar vs. inferior vs. 
multiple) and the side (left vs. right).
Statistical analyses
Statistical analyses consisted of two steps. First, means, 
medians and interquartile ranges or frequencies and propor-
tions were reported for continuous or categorical variables 
on the study population, respectively. Independent t test and 
Pearsons’ Chi square test were used to compare means and 
proportions. Second, multivariable logistic regression analy-
ses were used to assess the independent predictors of the risk 
of LNI at surgery and/or NP at follow-up. All statistical tests 
were performed using SPSS version 22 (IBM Corp., Somers, 
NY, USA). All tests were two-sided with a significance level 
set at p value < 0.05.
Results
Patients were treated with no LND (n  = 1424, 57%) or 
regional LND (hilar LND plus, on the right side, pre-retro-
caval nodes or, on the left side, para-aortic nodes, n  = 789, 
33%) or extended LND (regional plus interaortocaval nodes, 
n  = 244, 10%). Clinicopathologic features are summarized in 
Table 1. The prevalence of LNI was 7% (159/2485 patients) 
and 15% (159/1061 patients) in the overall and LND groups, 
respectively. In patients treated with radical nephrectomy 
(RN), the prevalence of LNI was 10% (158/1555 patients) 
and 0.1% (1/930 patients) in the partial nephrectomy (PN) 
group, respectively. When considering only patients who 
underwent LND (n  = 1061; 43%), the LNI rates were 18% 
and 12% in patients with right and left RCC, respectively 
(p = 0.02). After stratification according to RCC location, 
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LNI rates were 11, 10, 0, 12 and 26% for upper, middle, 
hilar, lower area and more than one kidney area, respec-
tively (p < 0.01). When considering only patients with single 
locations, no statistically significant difference was observed 
(p = 0.3).
The median number of removed lymph nodes (LNs) was 
6 (IQR 3-10). The median numbers of LNs removed were 5 
and 12 in patients undergoing regional and extended LND, 
respectively (p < 0.01). After stratification for RCC side, LNI 
at surgery was 15% and 8% for upper area, 11% and 9% 
for middle area, 14% and 10% for lower area, 0% and 0% 
for hilar area and 29% and 23% for more than one kidney 
area, in right and left RCC, respectively (Fig. 1, all p < 0.01). 
Table 1  Descriptive statistics of the overall population
Overall population
Gender, n  (%)
 Male 1788 (72%)
 Female 697 (28%)
Mean age, years (median IQR) 60 (62, 52–70)
Symptoms, n  (%)
 No symptoms 1591 (64%)
 Local and/or sistemic symptoms 894 (36%)





Clinical N stage, n  (%)
 cN0 2113 (85%)
 cN1 372 (15%)
Clinical M stage, n  (%)
 cM0 2206 (89%)
 cM1 279 (11%)
Tumour side, n  (%)
 Left 1199 (48%)
 Right 1286 (52%)
Tumour location, n  (%)
 Upper area 666 (27%)
 Middle area 654 (26%)
 Hilar area 26 (1%)
 Lower area 640 (26%)
 More than one area 470 (19%)
 Missing 30 (1%)
Type of surgical technique
 Open 2081 (84%)
 Minimally invasive 404 (16%)
Type of kidney surgery
 Partial nephrectomy 930 (37%)
 Radical nephrectomy 1555 (63%)
Histology type, n  (%)
 Clear cell carcinoma 1978 (80%)
 Chromophobe 136 (5%)
 Papillary type I 172 (7%)
 Papillary type II 147 (6%)
 Other 52 (2%)





Pathologic N stage, n  (%)
 pNx/pN0 2326 (93%)
 pN1 159 (7%)
Lymph node progression during follow-up
 Present 213 (9%)
Table 1  (continued)
Overall population
 Absent 2272 (91%)





Mean pathologic dimension, cm (median, IQR) 5.6 (5.3–7.5)
Lymphovascular invasion, n  (%)
 Yes 298 (12%)
 No 2187 (88%)
Necrosis, n  (%)
 Yes 951 (38%)
 No 1534 (62%)
Fig. 1  Lymph node invasion rates at surgery in 1061 patients under-
going non-standardized LND at a tertiary care center after stratifica-
tion for side and location of RCC (all p < 0.01). For each area, pro-
portions are expressed as the number of patients with pN1 disease at 
surgery over the number of patients undergoing LND
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When considering only patients with single locations, no 
statistically significant difference was observed (right RCC 
p = 0.5; left RCC p = 0.7).
The median follow-up period for uncensored cases was 
60 months. During the study period, the rate of NP was 
2.2%. After stratification for RCC side, LNI at surgery and 
NP at follow-up was 8% and 8% for superior area, 5% and 
4% for middle area, 8% and 7% for lower area, 8% and 0% 
for hilar area and 19% and 16% for more than one area, 
in right and left RCC, respectively (all p < 0.01, Fig. 2). 
When considering only patients with single involved area, 
no statistically significant difference was observed (right 
RCC p = 0.4; left RCC p = 0.1). In subgroup analyses on 
the overall population according to LND extent (namely 
no vs. regional vs. extended LND), patients not receiving 
LND with more than one kidney area had a higher pro-
portion of LNI and/or NP or only NP compared to other 
groups (2.6%, p = 0.004, Tables 2, 3, 4, 5). Higher but 
not statistically significant proportions of LNI and/or NP 
were always registered for patients with multiple RCC 
locations also in case of regional LND (17.8%, p = 0.08) 
and extended LND (48.9%, p = 0.1) in comparison to 
patients with single RCC locations. When focusing only 
on NP, patients with superior and inferior RCC locations 
had higher but not statistically significant proportions in 
comparison to other groups, 5.3% and 7.9% for regional 
LND (p = 0.07) and 9.2% and 9.4% for extended LND 
(p = 0.6). No statistically significant difference was seen 
when patients were stratified according to RCC side (all 
p ≥ 0.2).    
Additionally, after excluding T1a RCC patients 
(Tables 6, 7, 8, 9), in case of no LND, patients with mul-
tiple RCC locations (5.1%) had higher proportions of LNI 
and/or NP compared to single RCC locations (p = 0.01). In 
case of regional LND, higher proportions of LNI and /or 
NP were registered for patients with single inferior RCC 
location (19.4%) and multiple locations (18.9%) although 
not statistically significant (p = 0.1). While for patients 
undergoing extended LND, higher rates were registered for 
multiple RCC locations (48.4%) and superior single RCC 
location (40.4%, p = 0.2). No statistically significant dif-
ference was seen when patients were stratified according to 
RCC side (all p ≥ 0.2). When focusing only on NP, patients 
with superior and inferior RCC locations had higher but 
not statistically significant proportions in comparison to 
other groups, 6% and 9% for regional LND (p = 0.08) and 
8.8% and 10% for extended LND (p = 0.7). No statistically 
significant difference was seen when patients were strati-
fied according to RCC side (all p ≥ 0.3).
In multivariable analyses on the overall population, 
clinical metastatic status (cM1), clinical nodal status 
(cN1), pT2 and pT3/pT4 disease, Fuhrman grade 3/4 
were independent predictors of LNI at surgery and/or NP 
at follow-up (all p ≤ 0.01; Table 10), after adjusting for 
all the potential confounders. Conversely, neither the side 
(right vs. left), nor the location of RCC (upper vs. middle 
vs. hilar vs. lower area vs. more than one area) reached the 
independent predictor status (all p > 0.1; Table 10).
Fig. 2  Lymph node invasion rates at surgery in 1061 patients under-
going non-standardized LND at a tertiary care center after stratifica-
tion for side and location of RCC (all p < 0.01). For each area, pro-
portions are expressed as the number of patients with pN1 disease 
at surgery and/or nodal progression at follow-up over the number of 
patients surgically treated for RCC 
Table 2  Subgroup analyses 
according to LND extent 
for LNI and/or NP after 
stratification for the location of 
the tumor
Superior (%) Middle (%) Hilar (%) Inferior (%) Multiple (%) p value
No LND 0.3 0.2 0 0 2.6 0.004
Regional LND 10.5 11.8 5 17 17.8 0.08
Extended LND 37 30 0 29.7 48.9 0.1
Table 3  Subgroup analyses according to LND extent for LNI and/or 
NP after stratification for the side of the tumor
Left (%) Right (%) p value
No LND 0.7 0.7 0.9
Regional LND 13.3 14.5 0.6
Extended LND 33.3 41.6 0.2
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Discussion
Patients with nodal involvement in RCC have a eightfold 
greater chance of cancer-specific mortality compared to pN0 
counterparts [12, 13] and this has an independent prognos-
tic value even in patient with metastatic RCC [14]. Pub-
lished retrospective studies [2] have indeed failed to reach an 
agreement on the topic. Moreover, the EORTC 30881 [15] 
did not demonstrate any benefit in terms of cancer control, 
although today, roughly 70% of that study population would 
have been classified as cT1a-bN0M0. Moreover, the LNI 
rate in cT1–T2N0M0 RCC patients is actually low (namely 
2.2%) [16]. On the other hand, a sub-analysis of the EORTC 
30811 study, focusing only on cT3 tumors, showed a 15% 
overall survival benefit at 5 years for LND recipients [17]. 
Regardless of the effect of LND on cancer-specific survival, 
LND does maintain its key role in terms of staging and fol-
lowing prognostication for RCC patients. The majority of 
studies on the subject have indeed identified worse prog-
nosis for nodal positive RCC patients, both in M0 and M1 
settings [18]. For that reason, pathologic nodal assessment 
is of importance to tailor closer post-operative surveillance 
scheme or consideration of enrolment into adjuvant therapy 
trials [3]. Since nobody, to the best of our knowledge, has 
previously questioned the impact of RCC anatomical side 
and location, and therefore, the nodal spreading potential 
on the base of lymphatic drainage, on LNI at surgery and/or 
NP risk, we could observe that the rate of harboring nodal 
Table 4  Subgroup analyses 
according to LND extent for 
NP after stratification for the 
location of the tumor
Superior (%) Middle (%) Hilar (%) Inferior (%) Multiple (%) p value
No LND 0.3 0.2 0 0 2.6 0.004
Regional LND 5.3 2.8 5 7.9 2.1 0.07
Extended LND 9.2 5 0 9.4 4.4 0.6
Table 5  Subgroup analyses 
according to LND extent for NP 
after stratification for the side of 
the tumor
Left (%) Right (%) p value
No LND 0 0.2 0.2
Regional LND 3.9 5.5 0.6
Extended LND 7.4 6.8 0.8
Table 6  Subgroup analyses after exclusion of pT1a RCC according to LND extent for LNI and/or NP after stratification for the location of the 
tumor
Superior (%) Middle (%) Hilar (%) Inferior (%) Multiple (%) p value
No LND 2.8 0.7 0 0 5.1 0.01
Regional LND 11.9 15.2 5.6 19.4 18.9 0.1
Extended LND 40.4 37.5 0 31.7 48.4 0.2
Table 7  Subgroup analyses after exclusion of pT1a RCC according to 
LND extent for LNI and/or NP after stratification for the side of the 
tumor
Left (%) Right (%) p value
No LND 1.8 1.8 0.9
Regional LND 15.4 16.4 0.7
Extended LND 36 43.3 0.2
Table 8  Subgroup analyses 
after exclusion of pT1a RCC 
according to LND extent for 
NP after stratification for the 
location of the tumor
Superior (%) Middle (%) Hilar (%) Inferior (%) Multiple (%) p value
No LND 0.6 0.7 0 0 0 0.6
Regional LND 6 3.8 5.6 9 2.3 0.08
Extended LND 8.8 6.3 0 10 4.4 0.7
Table 9  Subgroup analyses after exclusion of pT1a RCC according to 
LND extent for NP after stratification for the side of the tumor
Left (%) Right (%) p value
No LND 0 0.6 0.5
Regional LND 4.5 6.3 0.3
Extended LND 8 6.7 0.7
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disease at surgery is not dissimilar after stratification for 
side of RCC. However when stratifying patients for RCC 
location (upper vs. middle vs. hilar vs. lower area vs. more 
than one area) and then considering only patients with sin-
gle locations (upper vs. middle vs. hilar vs. lower area), it 
appears that imbalances in proportions of patients with LNI 
at surgery and/or NP are exclusively due to patients with 
single-side RCC with more than one area affected in the 
overall population. In fact, patient with multiple location 
single-side RCC had higher proportions of LNI and/or NP 
in case of no LND (p =  0.004) and, although not statisti-
cally significant, also in regional (p =  0.08) and extended 
LND (p =  0.1) in comparison to patients with single-location 
single-side RCC. On the contrary, this was not confirmed 
when analyzing patients with only NP, since in this case, 
patients with superior or inferior location RCC, either after 
regional or extended LND, were more prone to recur in 
lymph nodes after surgery, although this was not statistically 
significant. To avoid potential confounding factors coming 
from a population with low nodal metastatic potential, T1a 
patients were excluded in the subsequent subgroup analysis. 
Nevertheless, the proportion of LNI and/or NP was higher 
for patients with multiple-location RCCs not receiving LND 
(p =  0.01) and after extended LND (p =  0.2), in comparison 
to other groups. As evaluated in the overall population, the 
rate of NP was higher for patients with superior and inferior 
single-side RCC either after regional and extended LND, 
although not statistically significant. These observation may 
be explained by considering that the intrarenal lymphatic 
system originates from the superficial network under the 
fibrous capsule and drains directly to the hilum or connects 
to the deeper cortical lymph capillaries, which after collect-
ing fluid from the connective tissue, travel in the renal sinus 
along blood vessels to the hilum [19, 20]. However, this 
system could branch off into the paracaval/para-aortal and 
the interaortocaval lymph nodes, but, as demonstrated by 
pioneering cadaveric and sentinel-node studies [6–9, 21–23], 
extreme variations in drainage among RCC patients could be 
observed, even with aberrant firstly draining thoracic nodes. 
Second, when considering the overall population (patients 
undergoing LND and not) and the risk of LNI at surgery and/
or NP at follow-up, neither the side nor the location of RCC 
reached the status of independent predictors. As expected, 
prognostic factors were represented by clinical metastatic 
status, clinical nodal status, pT2 and pT3/pT4 disease, and 
Fuhrman grade 3/4. These findings are in line with previous 
studies on the same topic [2, 18].
Despite several strengths, our analyses are not devoid of 
limitations, mainly due to its retrospective and non-com-
parative nature. First, patients underwent a LND with dif-
ferent template extensions according to tumor character-
istics and to preference of the surgeon. Second, any RCC 
histology was considered for the present analyses and this 
could have created an uneven population, due to different 
metastatic potential of each histologic type. Third, over the 
years, many aspects, as for the administration and type of 
recommended adjuvant treatment, have been changing in 
the oncosurgical management of patients with RCC and 
nodal involvement. On the other hand, to the best of our 
knowledge, this is the first study evaluating the risk of LNI 
and NP at follow-up, after stratification for the RCC side 
and location.
Conclusions
In patients with RCC, single-side tumors with involvement 
of more than one area, tend to have higher rates of nodal 
involvement relative to patients with single-area RCC 
location. However, neither the side (left vs. right) nor the 
location (upper vs. middle vs. hilar vs. inferior area) of the 
primary RCC tumor is related to the risk of harboring LNI 
at surgery and/or developing NP at follow-up.
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Table 10  Multivariable logistic regression analysis predicting nodal 
invasion at surgery and/or nodal progression at follow-up
OR 95% CI p value
Age 1 0.9–1 0.3
cM status (cM1 vs. cM0) 2.2 1.5–3.2 < 0.01
cN status (cN1 vs. cN0) 4.3 3–6.2 < 0.01
Pathologic diameter 1.1 1–1.1 < 0.01
Fuhrman grade (G3–G4 vs. G1–G2) 3.7 2.4–5.7 < 0.01
pT stage
 pT1 – – Ref.
 pT2 2.7 1.2–5.7 0.01
 pT3/4 5.4 2.9–9.9 < 0.01
RCC location
 Upper area – – Ref.
 Middle area 0.9 0.5–1.7 0.8
 Hilar area 0.3 0–2.6 0.3
 Lower area 1 0.6–1.7 0.9
 More than one area 0.8 0.4–1.2 0.3
Right vs. left kidney tumour 1.3 0.9–1.8 0.2
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The Effect of Anatomical Location of 
Lymph Node Metastases on Cancer 
Specific Survival in Patients with 
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Background: Positive nodal status (pN1) is an independent predictor of survival in 
renal cell carcinoma (RCC) patients. However, no study to date has tested whether the 
location of lymph node (LN) metastases does affect oncologic outcomes in a population 
submitted to radical nephrectomy (RN) and extended lymph node dissection (eLND).
Objective: To describe nodal disease dissemination in clear cell RCC (ccRCC) patients 
and to assess the effect of the anatomical sites and the number of nodal areas affected 
on cancer specific mortality (CSM).
Design, setting and partecipants: The study included 415 patients who underwent RN 
and eLND, defined as the removal of hilar, side-specific (pre/paraaortic or pre/paracaval) 
and interaortocaval LNs for ccRCC, at two institutions.
Outcome measurement and statistical analysis: Descriptive statistics were used to 
depict nodal dissemination in pN1 patients, stratified according to nodal site and number 
of involved areas. Multivariable Cox regression analyses and Kaplan-Meier curves were 
used to explore the relationship between pN1 disease features and survival outcomes.
Results and limitations: Median number of removed LN was 14 (IQR 9–19); 23% 
of patients were pN1. Among patients with one involved nodal site, 54 and 26% of 
patients were positive only in side-specific and interaortocaval station, respectively. The 
most frequent nodal site was the interaortocaval and side-specific one, for right and left 
ccRCC, respectively. Interaortocaval nodal positivity (HR 2.3, CI 95%: 1.3–3.9, p < 0.01) 
represented an independent predictor of CSM.
Conclusions: When ccRCC patient harbour nodal disease, its spreading can occur at 
any nodal station without involving the others. The presence of interoartocaval positive 
nodes does affect oncologic outcomes.
Patient summary: Lymph node invasion in patients with clear cell renal cell carcinoma 
is not following a fixed anatomical pattern. An extended lymph node dissection, during 
treatment for primary kidney tumour, would aid patient risk stratification and multimodality 
upfront treatment.
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INTRODUCTION
Positive nodal status and number of positive nodes are independent 
predictors of survival in renal cell carcinoma (RCC) patients (1, 2). 
Moreover, the role of lymph node dissection (LND) for RCC staging 
is widely accepted in intermediate/high risk patients, although its 
effect on cancer control is limited, especially in low risk patients 
(3). Adequate nodal staging and subsequent prognosis assessment 
become even more important in the light of the recent data 
published in the setting of adjuvant therapy, follow-up and salvage 
therapy (4–6).
The natural history of patients with nodal metastases is already 
known. Recently, it has been reported a 12% metastasis-free survival 
at 5 years (7). However, no study evaluated if prognosis is affected by 
location of the nodal metastasis or by the number of areas affected by 
nodal disease. This appears of paramount importance, if we consider 
that nodal invasion is often considered a criterion to define a RCC 
patient as metastatic, especially among medical oncologists.
Cadaveric dissection and sentinel-node studies (8–10) 
demonstrated wide heterogeneity of retroperitoneal lymphatic vessels 
anatomy. In addition, RCC histologies have different distant spreading 
rates (11) and oncologic outcomes (12, 13). Therefore, a critical 
analysis of nodal involvement areas in RCC patients submitted to RN 
and extended LND (eLND) might provide additional information on 
the pattern of lymphatic dissemination and its impact on the natural 
history of the disease.
Under such premises, the aim of this study was to describe 
nodal disease dissemination in clear cell RCC (ccRCC) 
patients and to assess the effect of the anatomical sites and the 




After institutional ethic committee board approvals (IRCCS San 
Raffaele, Milan and Ospedale Maggiore della Carita´, Novara, 
Italy), we identified 2,884 patients with sporadic, unilateral, RCC 
treated with open radical nephrectomy (RN) between 1980 and 
2012. Of these, 415 patients (14.4%) presented with clear cell 
RCC (ccRCC) histology and underwent RN plus eLND  (San 
Raffaele 165/415, 40% and Novara 250/415, 60%), defined by 
a template including hilar, side-specific (pre/paraaortic or pre/
paracaval) and interaortocaval nodal stations. All patients signed 
written informed consent to undergo surgery and to use clinical 
data in an anonymous fashion for scientific purposes. Nodal 
dissection template was shared between the Institutions, and 
ipsilateral template on the left side included nodes from the 
crus of the diaphragm to the inferior mesenteric artery, and 
on the right side, from the adrenal vein to the level of inferior 
mesenteric artery. Each nodal station was separately labelled 
and delivered to pathology (Figure 1).
The decision to perform LND was based on surgeon’s discretion 
and inclusion criteria were represented by cT2 disease and above, 
tumor size >10 cm, lymphadenopathies and palpable lymph 
nodes during surgery.
Outcomes
Outcomes were other cause mortality (OCM)- and cancer specific 
mortality (CSM)-free survival rate. Secondly, a description of the 
pattern of nodal cancer dissemination in pN1 patient was performed 
on the overall ccRCC population and after stratification according to 
the kidney tumour side (right vs. left). Finally, we assessed the CSM-
free survival rate according to the pattern of nodal dissemination 
(lymph node site or number of lymph node areas involved).
Covariates
Covariates consisted of age, gender, tumour side (right vs. left), 
symptoms, clinical metastatic status (cM0 vs. cM1), pathological 
T stage (defined according to 7th American Joint Committee on 
Cancer classification) (14), pathological N stage, Fuhrman grade 
(according to the WHO/International Society of Urological Pathology 
classification) (15), tumour size, mean number of lymph nodes 
removed, number of positive lymph nodes, number of involved nodal 
sites, hilar, side-specific and interaortocaval nodal status.
Statistical Analyses
Statistical analyses, as well as reporting and interpretation of the 
results, consisted of three steps.
Firstly, means, medians and interquartile ranges or frequencies and 
proportions were reported for continuous or categorical variables on 
the study population, respectively. Kaplan-Meier analyses were used 
to assess OCM- and CSM-free survival rate at different time points, 
on the overall population and after stratification for pN status.
Secondly, among patients with pN1 disease, a description of 
anatomical nodal involvement, stratified according to the number 
of the involved nodal sites (1 vs. 2 vs. 3) was performed.
FIGURE 1 |  Sketch of left and right nodal templates (left template in red and 
right template in blue), adapted from (2).
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Thirdly, among patients with pN1 disease, Cox multivariable 
regression analysis was used to predict the risk of CSM. 
Predictors consisted of number of involved lymph node areas, 
age, pT stage, pathologic tumour size, Fuhrman grade, and 
cM status. In an additional set of Cox multivariable regression 
analysis predicting CSM, anatomical nodal involvement (hilar 
vs. side-specific vs. interaortocaval nodal invasion) was used 
instead of number of involved lymph node areas. All statistical 
tests were performed using RStudio graphical interface v.0.98 
for R software environment v.3.0.2 (R Foundation, Vienna, 
Austria). All tests were two-sided with a significance level set at 
p value < 0.05.
RESULTS
Clinicopathologic features are summarized in Table 1. The median 
number of removed lymph nodes (LNs) was 14 (IQR 9–19) and the 
median number of positive LNs was 3 (IQR 2–8). Overall, 74 patients 
(18%) and 179 patients (43%) had systemic and local symptoms, 
respectively. Clinical M1 status was present in 112 patients (27%), 
pT3/pT4 disease was found in 260 patients (63%), while 199 (48%) 
had Fuhrman grade 3/4.
Median follow-up among survivors was 43.7 months, with an 
overall OCM- and CSM-free survival rate of 91 and 60%. The 1 year, 
3 year and 5 year OCM- and CSM-free survival rates were 97%, 93%, 
90% and 80%, 61%, 55%, respectively. When patients were stratified 
according to nodal status (namely, pN0 and pN1), pN0 patients had 
1 year, 3 year and 5 year CSM-free survival rates of 89, 72 and 66%, 
conversely pN1 patients’ CSM-free survival rates were 53, 20 and 
9% (p < 0.01; Figure 2). Median time to CSM in pN0 cM0 patients 
was 30 months.
Locations of nodal metastases are summarized in Figure 3 
and Table S1. Overall, within the group of patients with one 
positive nodal area, in 54% of patients metastatic dissemination 
skipped the hilar nodal area, while in 26% of cases, both the 
hilar and the side-specific areas were eluded. Instead, when 
looking at patients with two nodal areas involved, hilar nodal 
area was skipped in 54% of patients and side-specific area only 
in 4% of cases. Moreover after stratification for the ccRCC 
side, in case of interaortocaval-only nodal positivity among 
patients with one positive nodal site, 10 out of 12 patients 
had right ccRCC. This discrepancy was also identified in case 
of patients with two positive nodal areas and interaortocaval 
nodal involvement: the majority of patients had right ccRCC 
(14 out of 15 patients).
On Multivariable Cox regression analyses, when considering the 
location of nodal metastases, independent predictors of CSM were 
represented by pT3 (HR: 2.7; CI 95%: 1.5–5) and pT4 stage (HR: 6.1; 
CI 95%: 2.6–14.3), cM1 status (HR: 4.3; CI 95%: 3–6.2) and positive 
status of interaortocaval nodal area (HR: 2.3, CI 95%: 1.3–3.9), all 
p ≤ 0.01 (Table 2). Instead, when predicting CSM considering the 
number of positive nodal areas, independent predictors were pT3 
(HR: 2.6; CI 95%: 1.4–4.8) and pT4 stage (HR: 4.2; CI 95%:1.9–9.6), 
pathologic tumour size (HR: 1.1; CI 95%: 1–1.1), cM1 status (HR: 4.2; 
TABLE 1 |  Descriptive statistics of 415 patients submitted to radical 
nephrectomy and extended LND with clear cell renal cell carcinoma.
Variable Overall





No symptoms 162 (39.0%)
Local symptoms 179 (43%)
Systemic symptoms 74 (18%)
Site of primary tumour
Right 238 (57.3%)



























Mean pathologic tumour size (cm; median, IQR) 9 (8.5, 6–11.5)
Mean number of nodes removed (median, IQR) 15 (14, 9–19)
Mean number of negative nodes (median, IQR) 13 (12, 7–17)
















Mean time to last follow-up or death (months; 
median, IQR)
75.6 (43.7,  
12.8–117)
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CI 95%: 2.9–6) and presence of any number of nodal area involved 
(HR: 1.6–2.7; CI 95%: 1–5), all p < 0.05 (Table 3).
However when considering only pN1 patients, no difference was 
seen at Kaplan-Meier analysis in terms of CSM-free survival rate, after 
stratification of number of involved nodal areas (p = 0.5; Figure 4).
DISCUSSION
Patients with nodal involvement in RCC have an 7.8-fold greater 
chance of CSM compared to pN0 counterparts (16, 17) and 
this has an independent prognostic value even in patient with 
metastatic RCC (1). Published retrospective studies (18) have 
indeed failed to reach an agreement on the topic. Moreover, the 
EORTC 30881 (19) did not demonstrate any benefit in terms 
of cancer control. Nevertheless, today, roughly 70% of that 
study population would have been classified as cT1abN0M0. 
In this regards, a subanalysis focusing only on cT3 tumours, 
showed a 15% overall survival benefit at 5 years for LND 
recipients (20). Therefore, EAU guidelines recognize the role 
of LND for cN1, although its extent remains controversial, and 
suggest an eLND for cN0 patients, only in presence of adverse 
clinical features (21). However, the picture appears even more 
complex, when considering that RCC histologies can differ 
in terms of distant spreading rates (11, 12) and oncologic 
outcomes (13).
Several observations of the current study are of importance. 
First, we described the oncologic outcomes of eLND in ccRCC 
patients. Cancer-specific mortality-free survival rates were worse 
for pN1 patients at any time point, compared to pN0 ones. 
According to Blute et al., among ccRCC patients, estimated CSM-
free survival rates at 1-, 5- and 10 year follow-up were 95, 82 and 
72.5% for pNx/pN0 patients and 52, 21 and 11% for pN +patients 
(16). Discrepancies with our results could be ascribed to inclusion 
of only cM0 ccRCC population and to omission of LND in some 
patients (42% of the overall population, data not shown for ccRCC 
histology). Moreover the study lacked of a definition for the extent 
of LND.
FIGURE 2 |  Kaplan-Meier depicting CSM-free survival rate on the overall population after stratification for the pN status (p-value < 0.01). Blue line: pN0 patients; 
Green line: pN1 patients.
Nini et al.
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Second, for 54% of pN1 patients, disease eluded hilar nodal 
site (when considering patients with one or two positive nodal 
stations), in line with what has been previously reported by EAU 
guidelines (35–45%) (21). Only among patients with one positive 
nodal station, in 26% of patients, cancer skipped the hilar and 
the side-specific nodal stations. When looking at any patient 
with positive interaortocaval nodal station, the majority of them 
(n = 27/36, 75%) showed a right ccRCC. Focusing on those 
patients, with interaortocaval-only positive location of nodal 
metastases, 10/12 (83%) had right ccRCC. This observation is 
TABLE 2 |  Cox Logistic Regression analysis predicting CSM considering the location of nodal metastases.
UNIVARIABLE ANALYSES MULTIVARIABLE ANALYSES
VARIABLES HR (CI 95%) p-value HR (CI 95%) p-value
Positive hilar nodes 4.1 (2.7–6) <0.01 1.0 (0.6–1.8) 0.8
Positive side-specific nodes 4.2 (3–5.8) <0.01 1 (0.6–1.6) 0.9
Positive interaortocaval nodes 5 (3.4–7.3) <0.01 2.3 (1.3–3.9) <0.01
Age 1 (0.9–1) 0.9 1 (0.9–1) 0.2
pT stage pT2 vs. pT1 1.8 (0.9–3.5) 0.09 1.2 (0.6–2.5) 0.6
pT3 vs. pT1 5.6 (3.4–9.3) <0.01 2.7 (1.5–5) 0.01
pT4 vs pT1 21.6 (11.4–40.8) <0.01 6.1 (2.6–14.3) <0.01
Pathologic tumour size 1.1 (1.1–1.2) <0.01 1 (1–1.1) <0.01
Fuhrman grade 2.9 (2.1–4) <0.01 1.2 (0.9–1.8) 0.2
Clinical metastatic status 7.5 (5.5–10.2) <0.01 4.3 (3–6.2) <0.01
FIGURE 3 |  Nodal metastatic dissemination in the overall population and after stratification for the kidney site according to nodal areas and number of areas 
involved.
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line with the studies investigating the role of sentinel LND (9, 10). 
In the first paper, 7/14 patients presented with interaortocaval 
nodal positivity: 3 of them had interoaortocaval and side-specific 
nodal positivity, 2 interaortocaval-only nodal positivity and 2 
interaortocaval positivity and non-regional positivity; 6 of these 
patients had right kidney tumour. In the second, it was reported 
that right-sided tumour drained only to the paracaval nodes and 
left-sided tumours drained to the side-specific nodes.
It was formerly believed that RCC nodal drainage followed a fixed 
pattern, originating from the hilar region and branching off into the 
TABLE 3 |  Cox Regression analysis predicting CSM considering the number of locations of nodal metastases.
UNIVARIABLE ANALYSES MULTIVARIABLE ANALYSES
VARIABLES HR (CI 95%) p-value HR (CI 95%) p-value
Number of positive sites
1 vs. 0 4.5 (3–6.7) <0.01 1.6 (1–2.6) <0.05
2 vs. 0 5.3 (3.3–8.7) <0.01 1.7 (1–3) <0.05
3 vs. 0 6.5 (3.7–11.4) <0.01 2.7 (1.5–5) <0.01
Age 1 (0.9–1) 0.9 1 (0.9–1) 0.2
pT stage
pT2 vs. pT1 1.8 (0.9–3.5) 0.09 1.2 (0.5–2.4) 0.7
pT3 vs. pT1 5.6 (3.4–9.3) <0.01 2.6 (1.4–4.8) <0.01
pT4 vs. pT1 21.6 (11.4–40.8) <0.01 4.2 (1.9–9.6) <0.01
Pathologic tumour size 1.1 (1.1–1.2) <0.01 1.1 (1–1.1) <0.01
Fuhrman grade 2.9 (2.1–4) <0.01 1.2 (0.9–1.8) 0.2
Clinical metastatic status 7.5 (5.5–10.2) <0.01 4.2 (2.9–6) <0.01
FIGURE 4 |  Kaplan-Meier depicting CSM-free survival rate only in pN+ patients after stratification for the number of locations of nodal metastases (p = 0.5). Blue 
line: 1 positive nodal site; Green line: 2 positive nodal sites; Grey line: 3 positive nodal sites.
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Abstract
Background: The role of lymph node dissection (LND) during nephrectomy for renal cell carcinoma (RCC) is controversial. We looked at
the clinical usefulness of performing LND to stratify the risk of patients with RCC and select candidates for systemic treatment after nephrectomy.
Materials and Methods: We identified 730 patients with nonmetastatic RCC treated with nephrectomy and LND at a single center. We com-
pared the accuracy and clinical usefulness of a base model including factors defining high-risk patients according to the S-TRAC trial [(pT3 and
Grade≥2 and performance status score ≥1) or pT4] relative to the base model plus pN stage for the prediction of early progression after surgery.
Results: LN invasion resulted the most informative predictor of early progression (odds ratio: 6.39; 95% confidence interval [CI]: 3.26,
12.54; P < 0.0001). The accuracy was higher (P = 0.008) for the model implemented with pN (area under the curve: 0.76; 95% CI: 0.71,
0.80) as compared to the base model (area under the curve: 0.72; 95% CI: 0.68, 0.76). Performing LND to select patients for postoperative
systemic treatment, resulted in a slightly higher net benefit as compared to a strategy defining risk on the base of factors other than pN.
Patients with high-risk disease showed a large difference in the risk of progression according to pN-status (1-year risk: 58% [95% CI: 45,
72] for pN1; 31% [95% CI: 25, 38] for pN0; P < 0.001).
Conclusions: Performing LND at the time of nephrectomy improves risk stratification, resulting into a small but nonnegligible clinical
advantage for selecting high-risk patients for further treatment after surgery. Further trials should investigate whether high-risk pN1 patients
would benefit from a different postoperative management. ! 2019 Elsevier Inc. All rights reserved.
Keywords: Renal cancer; Lymph node dissection; Lymph node metastasis; Adjuvant therapy; Staging
1. Introduction
The role of lymph node dissection (LND) in the manage-
ment of renal cell carcinoma (RCC) has been largely inves-
tigated and is still controversial [1,2].
Currently available evidence does not support a survival
advantage for RCC patients treated with nephrectomy and
LND. Indeed, a randomized trial and several retrospective
studies have failed to prove higher disease-free and overall
survival rates associated with LND [1,3−11]. However, the
prognostic value of positive LNs is undeniable, with a num-
ber of previous studies demonstrating an increased cancer-
specific and overall mortality for patients found with pN1
disease at the time of nephrectomy [12−16]. As such, the
staging role of LND may be crucial for the management of
patients with RCC: patients with nodal disease could be
selected for a more intensive surveillance protocol; more
*Corresponding author. Tel.: +39 02 26435506; fax: +39 02 26432969.
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importantly, they may be the optimal candidates for adju-
vant systemic treatments after surgery.
The US Food and Drug Administration has recently
approved sunitinib for the adjuvant treatment of patients at
high risk of recurrent RCC following nephrectomy. The
approval was based on the results of the S-TRAC trial test-
ing the effect of adjuvant sunitinib in patients with high-
risk nonmetastatic clear cell cancer [17]. Patients treated
with sunitinib had a significantly longer median disease-
free survival as compared to placebo. When stratifying the
cohort according to disease characteristics, patients at
higher risk for recurrence, defined on the base of disease
stage, Fuhrman grade and on the Eastern Cooperative
Oncology Group (ECOG) Performance Status (PS), har-
bored a 26% lower risk of disease progression associated
with adjuvant treatment after surgery. Translating these
results into clinical practice, we could argue that those
patients are the ones who may greatly benefit from systemic
therapy after nephrectomy, although other randomized tri-
als did not confirm a survival advantage with adjuvant treat-
ment [18,19]. Interestingly, patients with pN1 disease were
classified as high risk regardless of all other risk factors
[17]; as such, performing LND at the time of surgery could
allow to detect patients with LN metastases who may other-
wise not be selected for adjuvant treatments on the solely
base of T stage, disease grade and PS. In this case LN stag-
ing would greatly influence clinical practice; however, in
the S-TRAC trial a LND was not routinely performed and
not standardized, thus leaving the question unanswered.
To evaluate the clinical advantage of performing LND to
identify nonmetastatic high-risk patients who may benefit
from systemic treatment after surgery, we tested if the addi-
tion of nodal staging in a model accounting for factors that
were used to define high-risk disease in the S-TRAC trial
would result in a higher accuracy for predicting early disease
progression after surgery, in a cohort of patients treated with
nephrectomy and LND at a single academic center.
2. Methods
After institution review board approval, we collected
data from a cohort of 861 patients with nonmetastatic RCC
who were treated with nephrectomy and LND from 1987 to
2016 at a single academic center.
All patients had histology-proven clear cell disease and
were free of metastases at preoperative staging. Clinical and
pathologic data, including the ECOG-PS score, pathologic
stage (TNM classification) and Fuhrman grade were collected
for each patient. Histological tumor necrosis was defined as
the presence of any microscopic coagulative tumor necrosis.
A sarcomatoid component was defined as a spindle cell
malignancy with histological appearance of a sarcoma. No
patient received either neoadjuvant or adjuvant therapy.
The LND procedure was performed based on the clini-
cal judgment of each treating physician, according to
preoperative patient and cancer characteristics and
intraoperative assessment by direct palpation. The proce-
dure consisted of excising the fibro-fatty tissue along
anatomically defined areas (hilar, interaortocaval, para-
aortic, pre-, and retrocaval) as previously described [20].
The follow-up was based on clinical evaluation and chest-
abdomen CT scans performed at 3 to 6 months and at
12 months after surgery over the first year, and annually
thereafter. Additional imaging assessments were performed
if the patient’s symptoms raised clinical suspicion of relapse.
Disease progression after surgery was defined as the evi-
dence of retroperitoneal or distant recurrence demonstrable
on imaging at least 1 month after treatment; patients who
did not experience relapse were censored at the date at the
last follow-up.
Patients missing clinical or pathologic data (131
[15.8%]) relevant to the study outcome were excluded from
the analysis.
2.1. Statistical analysis
The aim of the study was to test whether adding pN stage
to a model including factors identifying patients at high risk
of progression according to the criteria defined within the
S-TRAC randomized clinical trial ([T3 disease and Fuhrman
grade ≥2 and performance status score ≥1] or T4 disease)
[17] would improve disease-risk stratification. Therefore, we
compared a model including pT stage, disease grade and
ECOG-PS with a same model implemented with pN stage,
in terms of the accuracy for predicting early disease progres-
sion after surgery, defined as relapse within 12 (§3) months
post-treatment. We selected this outcome as a clinically rea-
sonable indicator of patients who may deserve adjuvant treat-
ment after surgery. Moreover, given that performing a LND
in all cases would not represent the everyday clinical prac-
tice, we tested the accuracy of a third model mirroring a risk-
based strategy to select patients for LND: we used a reliable
and externally validated risk score [21,22] identifying
patients with 2 or more risk factors for LN invasion (e.g.,
tumor size ≥10 cm; Fuhrman grade ≥3; pT ≥3; tumor necro-
sis; sarcomatoid component) as deserving LND. Those
patients were included in the model considering the actual
pN stage (e.g., N0 or N1), while those with less than 2 risk
factors for positive LNs were considered as pNx/pN0 regard-
less of their pN status. Logistic regression analysis was used
considering early disease progression as a binary outcome:
patients were considered to have progressed if disease was
evident at follow-up assessments within 12 months after sur-
gery; likewise, patients were considered free from early pro-
gression if they had a last negative assessment at 12 months
or at further follow-up, or if they relapsed after 12 months
from surgery. Patients with a last negative follow-up before
9 months postsurgery (n = 20) and those with a recurrence
after 15 months but without a previous negative assessment
within the 12 (§3) months window (n = 6) were excluded
from the early progression outcome analysis. As a sensitivity
analysis, we included all patients with follow-up data, using
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the assessment closest to 1 year; moreover, we checked for
the potential influence of year of surgery and of the number
of LN removed by including these factors in the multivari-
able model.
The accuracy of the predictive models was assessed by
area under the curve (AUC). We used decision curve analy-
sis to evaluate the clinical consequences of model predic-
tions by comparing net benefit, based on true positives and
false positives, at various threshold probabilities of progres-
sion [23]. Because it is unlikely that a physician would sub-
mit a patient to adjuvant treatment if the probability of
early progression was <5% or would avoid additional treat-
ment for patients with a probability higher than 40%, we
examined the range of threshold probabilities between 5%
and 40%. The accuracy of the models and decision curves
was corrected for overfitting using 10-fold cross-validation.
Finally, we used Kaplan-Meier analysis to estimate the
risk of disease progression and overall mortality of high-risk
patients with either pN0 or pN1 disease. Statistical analyses
were conducted using Stata 15.0 (StataCorp, College Station,
TX), with a 2-sided significance level set at P < 0.05.
3. Results
Table 1 reports the clinical and pathological characteris-
tics of the entire cohort (n = 730). The majority of patients
was treated with radical nephrectomy (95%). Lymph node
metastases were found in 7% of cases; according to the
S-TRAC trial definition, 257 (35%) patients would be cate-
gorized as high-risk; of them, 21% had pN1 disease. A total
of 341 (47%) patients would deserve a LND according to a
risk-based approach [21,22]. In our cohort, this approach
showed a good accuracy (AUC: 0.70; 95% confidence
interval [CI]: 0.64−0.75) with a sensitivity of 83.3% a spec-
ificity of 56.2% and a positive and negative predictive value
of 13.2% and 97.7%, respectively.
At logistic regression analysis, pN stage was significantly
associated with early disease progression when included in a
model accounting for the other factors defining patients at
high-risk (Table 2) both when considering pN stage as all
patients would receive a LND (e.g., N0 vs. N1; odds ratio:
6.39; 95% CI: 3.26, 12.54; P < 0.0001) and when consider-
ing the pN status only for patients who would undergo a
LND according to a risk-based approach (e.g., NX/0 vs. N1;
odds ratio: 5.63; 95% CI: 2.72, 11.68); P < 0.0001). The pre-
dictive models implemented with pN stage showed a signifi-
cantly higher accuracy (P = 0.008), with an AUC of 0.76
(95% CI: 0.71, 0.80) and 0.75 (95% CI: 0.71, 0.79) for model
2 and 3, respectively, as compared to 0.72 (95% CI: 0.68,
0.76) for the base model, after cross-validation.
Decision curve analysis shows the clinical benefit of
using each model to select patients at high-risk of early pro-
gression who may benefit from systemic treatment postsur-
gery (Fig. 1). The models including pN stage showed a
slightly higher net benefit, which looks prominent for
threshold probabilities higher than 30%: if we accept a
threshold risk of progression ranging from 10% to 35%, a
strategy accounting for pN status would allow to detect
from 0.3% to 1.6% more patients at high risk eventually
deserving adjuvant treatment, without any unnecessary
treatment. Comparable results were observed when consid-
ering a strategy submitting to LND only patients at higher
risk of LN invasion (Fig. 1).
Table 1
Clinical and pathological characteristics of the entire cohort (n = 730) of
nonmetastatic RCC patients.
Age [yrs] Median(IQR) 60 (51, 69)






















Histological tumor necrosis 358 (49%)
Histological sarcomatoid component 29 (4.0%)

















High-risk patientsb 257 (35%)
pN0 203 (79%)
pN1 54 (21%)
Follow-up [mos] Median(IQR) 49 (13, 125)
ECOG-PS = Eastern Cooperative Oncology Group-Performance Status;
LN = lymph nodes.
a Including: tumor size ≥10 cm; Fuhrman grade ≥3; pT ≥3; tumor necro-
sis; sarcomatoid component [21,22].
b Defined as pT3 and Fuhrman grade ≥2 and ECOG-PS≥1 or pT4 or
pN1, as described in the S-TRAC [17].
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Moreover, high-risk nonmetastatic patients with pN1
disease showed significantly worse outcomes (Fig. 2), with
a risk of disease progression at 1 year post-treatment of
58% (95% CI: 45, 72) as compared to 31% (95% CI: 25,
38) for high-risk patients with negative LNs (P = 0.0001;
Table 3). Likewise, the estimated 1-year overall mortality
risk was 33% (95% CI: 22, 48) and 13% (95% CI: 9, 18)
for node-positive and node-negative nonmetastatic high-
risk patients (P < 0.0001).
Same results were found at sensitivity analyses including
all patients with at least 1 follow-up assessment but who
were not evaluated within the eligible time frame; more-
over, the number of LNs removed and the year of surgery
were not independently associated with early progression
when included in the multivariable logistic model (all P >
0.4; Supplementary Table 1).
4. Discussion
We looked at the clinical advantage of performing LND
to better stratify the risk of postoperative progression of
RCC and to identify patients at high-risk who may deserve
additional treatments after surgery. Our interest was fueled
by the recent findings of the S-TRAC trial suggesting that
patients considered at high-risk of progression may benefit
more from adjuvant systemic treatment [17]. Those patients
were defined by local T-stage, disease grade and PS or by
pN stage if LND was performed. Our results showed that
the information on LN status allows for higher accuracy in
the prediction of early progression after surgery. However,
performing LND in each case to include pN stage in risk-
stratification would allow to detect less than 2% more
patients potentially deserving additional treatment, as com-
pared to a strategy assessing patients-risk according to risk
factors other than LN status. Similar results would be
obtained when performing LND only in patients at higher
risk of positive LNs according to a risk-stratification tool
[21,22]. In light of these findings, the clinical advantage of
performing a time-consuming and challenging procedure
like retroperitoneal LND might be considered questionable.
On the other hand, LND has shown low perioperative mor-
bidity [5,24,25]: in a recently matched-cohort analysis,
nephrectomy along with LND was associated with a com-
parable risk of Clavien grade ≥3 complications as com-
pared to nephrectomy alone [24]. As such, even a slightly
higher clinical benefit for detecting high-risk patients could
justify performing LND for staging purpose, at least in
those at higher risk for LN invasion.
Previous studies confirmed the independent prognostic
significance of LN status in RCC patients [1,7,12−16]: in a
large multicenter cohort of 3,507 patients, Capitanio et al.
showed that pN1 disease was associated with a 3.2 times
higher risk of cancer-specific mortality after adjusting for T
Table 2
Logistic regression model predicting disease progression within 12 months; model 1 accounting for factors defining high-risk nonmetastatic patients regard-
less of pN stage; model 2 accounting for factors defining high risk patients including pN stage and assuming that all patients would receive lymph node dis-
section; model 3 including pN stage only for patients at high risk of positive nodes who would undergo lymph node dissection.
Model 1 Model 2 Model 3
OR 95% CI 95% CI OR 95% CI P value OR 95% CI P value
pT stage
pT1-2 vs. pT ≥3
5.56 3.61, 8.56 <0.0001 4.95 3.18, 7.71 <0.0001 4.70 3.02, 7.31 <0.0001
ECOG-PS score
0 vs. ≥1
1.34 0.87, 2.08 0.2 1.28 0.81, 2.02 0.3 1.29 0.82, 2.02 0.3
Fuhrman grade
G1 vs. G ≥2
5.55 1.31, 23.47 0.02 5.09 1.20, 21.59 0.02 5.13 1.21, 21.71 0.02
pN stage
0/x vs. 1
− − − 6.39 3.26, 12.54 <0.0001 5.63 2.72, 11.68 <0.0001
ECOG-PS = Eastern Cooperative Oncology Group-Performance Status.
Fig. 1. Decision curve analysis assessing net benefit for prediction of dis-
ease progression within 12 months after surgery in high-risk nonmetastatic
patients. The red line represents the net benefit of using a risk stratification
model without lymph node status. The blue line represents the net benefit
of using a risk stratification considering lymph node status and assuming
that all patients would receive a lymph node dissection. The orange line
represents the net benefit of using a risk stratification considering lymph
node status only for patients who would receive a lymph node dissection
according to the risk of lymph node invasion. The dashed line represents
the “treat-all” strategy. The gray line represents the “treat−none” strategy.
(Color version of figure is available online.)
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stage and Fuhrman grade [12]; similarly, in a population-
based cohort study, the percentage of positive nodes
emerged as an independent predictor of post-treatment mor-
tality when included in a model accounting for several clin-
ical and pathological factors [13].
Patients with positive LNs have shown worse oncological
outcomes in several series [1,7,26,27]. Gershman et al.
recently analyzed the long-term survival of 138 patients with
isolated LN involvement after nephrectomy [26]: the 5-year
CSS and OS rate were only 26% and 25%, with a median
time to development of metastases of 4.2 months. Similar
data were reported in other series, with a postoperative
5-year CSS rate ranging from 22% to 39% for pN1 patients
[1]. In line with these findings, we observed that even among
patients with high-risk disease, those with LNs metastases
showed about 2-fold higher probability of progression and
overall mortality as compared with same risk node negative
patients. These results, suggest that LND may be of particu-
lar value for high-risk nonmetastatic patients, by further strat-
ifying disease risk and inform postoperative management.
Indeed, we could argue that postoperative adjuvant treatment
may lead to a greater survival advantage in high-risk patients
with pN1 disease relative to pN0; at the same time, given the
large difference observed in the risk of progression, patients
with LN metastases may benefit from different therapeutic
protocols as compared to high risk node negative patients.
These findings call for further clinical trials, including large
cohorts of patients properly staged for LN disease at the time
of nephrectomy, aimed to better define the best candidates
for additional treatments after surgery.
Our study has some limitations. As a retrospective anal-
ysis there is a risk of selection bias, which might have influ-
enced the results. Indeed, by including only patients treated
with LND, we could have selected those at higher risk of
LN metastasis and therefore submitted to nephrectomy
along with LND; indeed, the majority of patients received a
radical nephrectomy, even for low stage disease. However,
about 40% of patients included were staged as T1, thus sug-
gesting that even lower risk patients received a LND. More-
over, we applied a validated risk score used to define
patients at high risk of positive LNs who would deserve a
LND: according to this score 53% of patients would not be
submitted to LND. As such, our cohort could be considered
as representative of the majority of patients commonly sub-
mitted to surgical treatment for RCC in clinical practice.
The number of LNs removed was not equal for every
patient. Some of them could have received a suboptimal stag-
ing thus potentially altering the results. However, the number
Table 3
Estimated oncological outcomes of high risk nonmetastatic RCC patients treated with surgery, according to Kaplan-Meier analysis.
Risk of disease progression (95% CI) High risk pN0 High risk pN1 P value
6 mos 22% (17, 28) 43% (31, 58) 0.0001
12 mos 31% (25, 38) 58% (45, 72)
24 mos 41% (35, 49) 68% (55, 81)
60 mos 59% (52, 67) 79% (64,90)
Risk of overall mortality (95% CI)
6 mos 5% (3, 10) 15% (8, 28) <0.0001
12 mos 13% (9, 18) 33% (22, 48)
24 mos 21% (16, 27) 56% (43, 71)
60 mos 44% (37, 52) 80%(67, 90)
Fig. 2. Estimated probability of disease free survival (a) and overall sur-
vival (b); the red line represents high-risk nonmetastatic patients with pN0
disease; the blue line represents high-risk nonmetastatic patients with pN1
disease. The log-rank test indicate significant difference between groups
(P < 0.0001). (Color version of figure is available online.)
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of LNs removed was not significantly associated with the risk
of early progression when included in the multivariable model.
Finally, considering the large time interval covered by
our study, patients could have been treated differently in
more recent years, eventually resulting in better outcomes.
To control for this bias we checked for the influence of the
year of surgery on the risk of disease progression without
observing a significant correlation.
5. Conclusions
Our results suggest that performing LND at the time of
nephrectomy for RCC would result in a small clinical
advantage for selecting candidates to further treatment after
surgery. However, LND allows to better define the risk of
progression even among high-risk cases. Whether patients
with high-risk nonmetastatic RCC may benefit from a dif-
ferent postoperative management according to LN status
needs to be investigated in further clinical trials.
Supplementary materials
Supplementary material associated with this article can
be found in the online version at https://doi.org/10.1016/j.
urolonc.2019.01.009.
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